• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FVIII基因第22外显子中的Tyr2105Cys突变是轻度/中度A型血友病患者产生抑制物的一个风险因素。

Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.

作者信息

Franchini M, Girelli D, Olivieri O, Castaman G, Lippi G, Poli G, Salvagno G L, Tagariello G, Giuffrida A, de Gironcoli M, Morfini M, Berntorp E, Gandini G

机构信息

Servizio di Immunoematologia e Trasfusione-Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy.

出版信息

Haemophilia. 2006 Jul;12(4):448-51. doi: 10.1111/j.1365-2516.2006.01297.x.

DOI:10.1111/j.1365-2516.2006.01297.x
PMID:16834751
Abstract

We report the case of a patient with mild haemophilia A, due to a Tyr2105Cys mutation in exon 22 of the C1 domain, who developed a high-titre factor VIII inhibitor (maximum titre 1600 BU) with recurrent severe haemorrhages and fatal intracranial bleeding. Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high-titre inhibitors.

摘要

我们报告了一例轻度甲型血友病患者的病例,该患者因C1结构域第22外显子中的Tyr2105Cys突变而发病,其出现了高滴度的凝血因子VIII抑制物(最高滴度为1600 BU),伴有反复严重出血和致命性颅内出血。根据已发表的数据,虽然这种突变在轻度或中度甲型血友病患者中很少发生,但它经常与高滴度抑制物的形成有关。

相似文献

1
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.FVIII基因第22外显子中的Tyr2105Cys突变是轻度/中度A型血友病患者产生抑制物的一个风险因素。
Haemophilia. 2006 Jul;12(4):448-51. doi: 10.1111/j.1365-2516.2006.01297.x.
2
Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.在一个严重血友病 A 患者的单中心队列中,F8 基因突变类型对抑制剂发展的影响。
Haemophilia. 2011 Mar;17(2):275-81. doi: 10.1111/j.1365-2516.2010.02420.x. Epub 2010 Nov 11.
3
Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population.奈梅亨甲型血友病患者群体中凝血因子VIII基因的13种新突变。
Br J Haematol. 2005 Oct;131(1):109-17. doi: 10.1111/j.1365-2141.2005.05737.x.
4
Frequency of factor VIII (FVIII) inhibitor in haemophilia A.甲型血友病中凝血因子 VIII(FVIII)抑制剂的发生率。
J Coll Physicians Surg Pak. 2012 May;22(5):289-93.
5
Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.在先前未经治疗或仅接受过极少治疗的甲型血友病患者中,接触血浆源性溶剂去污剂因子VIII浓缩物后抑制剂的出现情况。
Haemophilia. 2006 Mar;12(2):128-32. doi: 10.1111/j.1365-2516.2006.01201.x.
6
Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.利妥昔单抗用于治疗对传统化疗难治的高滴度获得性凝血因子VIII抑制物患者。
Haemophilia. 2007 Jan;13(1):46-50. doi: 10.1111/j.1365-2516.2006.01342.x.
7
Characteristics of inhibitors in mild/moderate haemophilia A.轻度/中度甲型血友病中抑制剂的特征
Haemophilia. 2006 Dec;12 Suppl 6:43-7. doi: 10.1111/j.1365-2516.2006.01365.x.
8
Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.成功诱导低剂量免疫耐受治疗严重血友病 A 伴低于 40 贝塞斯达单位抑制剂
Haemophilia. 2010 May;16(102):71-9. doi: 10.1111/j.1365-2516.2010.02225.x.
9
Risk of inhibitor development in mild haemophilia A increases with age.轻型血友病 A 患者的抑制剂发生风险随年龄增长而增加。
Haemophilia. 2012 Mar;18(2):263-7. doi: 10.1111/j.1365-2516.2011.02629.x. Epub 2011 Aug 19.
10
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.轻度和中度血友病A中的凝血因子VIII抑制剂。英国血友病中心主任组织。
Thromb Haemost. 1998 Apr;79(4):762-6.

引用本文的文献

1
Neurological Complications Associated with Hereditary Bleeding Disorders.遗传性出血性疾病相关的神经系统并发症。
Curr Neurol Neurosci Rep. 2023 Nov;23(11):751-767. doi: 10.1007/s11910-023-01313-y. Epub 2023 Oct 21.
2
Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A.在轻度和中度血友病 A 患者中消除因子 VIII 抑制剂。
Am J Hematol. 2012 Sep;87(9):933-6. doi: 10.1002/ajh.23269. Epub 2012 Jun 26.
3
Immune response to FVIII in hemophilia A: an overview of risk factors.甲型血友病患者对凝血因子VIII的免疫反应:风险因素概述
Clin Rev Allergy Immunol. 2009 Oct;37(2):58-66. doi: 10.1007/s12016-009-8118-1.
4
Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.轻度/中度甲型血友病的抑制剂:两例病例报告及文献综述
Blood Transfus. 2008 Jul;6(3):163-8. doi: 10.2450/2008.0031-07.
5
Acquired haemophilia A as a blood transfusion emergency.获得性血友病A作为输血紧急情况
Blood Transfus. 2008 Jan;6(1):8-11. doi: 10.2450/2008.0030-07.